SEOUL, November 27 (AJP) - South Korean pharmaceutical company GI Innovation has been chosen to participate in national drug development projects funded by the Korea Drug Development Fund (KDDF).
This initiative aims to bolster the nation's pharmaceutical industry and enhance public health by supporting the entire drug development pipeline.
On Tuesday, GI Innovation announced that its first project will center on the immunotherapy agent GI-102. The two-year research endeavor will prioritize securing technology transfer and expedited regulatory approval. The company plans to conduct combination therapy trials of GI-102 in both subcutaneous (SC) and intravenous (IV) formulations with Keytruda (pembrolizumab), a renowned humanized antibody. GI-102 has shown promising results in increasing the number of immune cells by up to fivefold.
The second project will focus on GI-128, a bispecific antibody designed to target multiple components of the immune system. The two-year research period will be dedicated to developing optimized candidate molecules, enabling a swift transition to preclinical testing and early opportunities for technology transfer.
GI-128 merges two antibodies: one that inhibits PD-L1, a molecule known to help tumors evade immune detection, and another that targets macrophages, specialized cells responsible for clearing cellular debris and pathogens.
Copyright ⓒ Aju Press All rights reserved.
